Method and system for reducing the likelihood of colorectal cancer in a human being

• US 10,548,761 B2
• Filed: 09/26/2018
• Issued: 02/04/2020
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik
• Inventors: Kovarik, Joseph E.
• Primary Examiner(s): Gangle, Brian
• Application Number:
  US16/142,171
• Publication Number:
  US 20190029871A1
• Time in Patent Office: 496 Days
• Field of Search: None
• CPC Class Codes: A61F 5/566 Intra-oral devices
• CPC Class Codes: A61K 31/733 Fructosans, e.g. inulin
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual'"'"'s gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

Claims

1. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising:

substantially reducing the human being'"'"'s resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii; and

providing fructan fiber inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon to enhance intestinal Mg.sup.2+ absorption by the human being.

2. The method of claim 1, wherein the Faecalibacterium prausnitzii bacteria employed are first isolated from a human being'"'"'s stool.

3. The method of claim 1, wherein the Faecalibacterium prausnitzii bacteria employed are from the human being treated.

4. The method of claim 1, further comprising reducing H. pylori populations in the individual human being.

5. The method of claim 1, wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53.

6. The method of claim 1, wherein said bacterial formulation further includes a microbe selected from the group consisting of Streptococcus, Veillonella, Fusobacterium and Treponema.

7. The method of claim 1, wherein the bacterial formulation further comprises a bacterium selected from the group consisting of Chlamydia, Shigella flexneri, Mycoplasma bacteria, and H. pylori.